Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $175.67 in the latest trading session, marking a -1.68% move from the prior day.

Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Mark Vickery headshot

Top Analyst Reports for NVIDIA, Booking Holdings & Altria

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Booking Holdings (BKNG), and Altria Group (MO).

Moderna (MRNA) Stock Moves -0.83%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.

Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate

by Zacks Equity Research

Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.

J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

by Zacks Equity Research

J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

by Zacks Equity Research

Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $159.87, moving -0.1% from the previous trading session.

Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study

by Zacks Equity Research

Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Sweta Killa headshot

JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm

by Sweta Killa

The U.S. regulators recommended an immediate pause on the use of Johnson & Johnson's (JNJ) COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

by Zacks Equity Research

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.

Stock Market News for Apr 14, 2021

by Zacks Equity Research

The S&P 500 and the Nasdaq closed in the green on Tuesday backed by solid gains in tech stocks.

Kinjel Shah headshot

Which Vaccine Maker Will Win the Fight Against COVID-19?

by Kinjel Shah

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation

by Zacks Equity Research

FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.

Mark Vickery headshot

S&P 500 Hits Another New All-Time High

by Mark Vickery

The index's totals weren't super-noteworthy in the daily performance, +0.33%, but this April has seen multiple new highs four of the past six sessions.

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

by Zacks Equity Research

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study

by Zacks Equity Research

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Consumer Price Index Rise 0.6%

by Zacks Equity Research

Consumer Price Index Rise 0.6%

Mark Vickery headshot

CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?

by Mark Vickery

Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.

Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study

by Zacks Equity Research

Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?